Larimar Therapeutics Files 8-K with Material Agreement

Ticker: LRMR · Form: 8-K · Filed: Jul 31, 2025 · CIK: 1374690

Larimar Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyLarimar Therapeutics, Inc. (LRMR)
Form Type8-K
Filed DateJul 31, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: material-agreement, filing

Related Tickers: LRMR

TL;DR

Larimar Therapeutics (LRMR) filed an 8-K on 7/29, reporting a material definitive agreement. Expect updates.

AI Summary

On July 29, 2025, Larimar Therapeutics, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes financial statements and exhibits, with the report being publicly available as of July 31, 2025. Larimar Therapeutics, formerly known as Zafgen, Inc., is incorporated in Delaware and operates in the pharmaceutical preparations industry.

Why It Matters

This 8-K filing indicates a significant new agreement for Larimar Therapeutics, which could impact its business operations and future financial performance.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new risks or opportunities that may affect the company's stock price.

Key Players & Entities

  • Larimar Therapeutics, Inc. (company) — Registrant
  • Zafgen, Inc. (company) — Former company name
  • July 29, 2025 (date) — Date of earliest event reported
  • July 31, 2025 (date) — Date filed
  • Delaware (jurisdiction) — State of incorporation
  • Three Bala Plaza East, Suite 506 (address) — Principal executive offices
  • Bala Cynwyd, Pennsylvania (location) — Principal executive offices location
  • 19004 (zip_code) — Principal executive offices zip code
  • 20-3857670 (ein) — I.R.S. Employer Identification No.
  • 001-36510 (commission_file_number) — Commission File Number

FAQ

What is the nature of the material definitive agreement filed by Larimar Therapeutics?

The 8-K filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the excerpt.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing was on July 29, 2025.

What is Larimar Therapeutics' former company name?

Larimar Therapeutics, Inc. was formerly known as Zafgen, Inc.

In which state is Larimar Therapeutics incorporated?

Larimar Therapeutics, Inc. is incorporated in Delaware.

What is the business address of Larimar Therapeutics?

The business address of Larimar Therapeutics is Three Bala Plaza East, Suite 506, Bala Cynwyd, Pennsylvania, 19004.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on July 31, 2025 regarding Larimar Therapeutics, Inc. (LRMR).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.